Today: 11 februari 2026
Subscribe
Search result

Phantom 4 RTK/feed/category/dji-matrice-30t-pl- Page 274

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly shares closed near $863 on Oct. 31, up about 10% for the month and close to a 52-week high. Q3 revenue jumped 54% to $17.6 billion, driven by surging demand for GLP-1 drugs Mounjaro and Zepbound, with U.S. GLP-1 market share at 57%. Management raised 2025 sales and EPS guidance sharply. The company recently won FDA approval for Inluriyo and expanded Walmart access for Zepbound.
2 november 2025
AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

AMTD Digital shares surged 224% to a $5.47 intraday high on Oct. 31, 2025, before closing up 75% at $2.95, with trading volume topping 323 million shares. The company reported a 1,085.9% year-over-year revenue jump to $73.2 million for the half-year ended April 2025, driven by its TGE acquisition. Net profit hit $51.5 million, but most gains came from one-off investment income. HKD now trades near $3.00.
3 november 2025
IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories reported Q3 2025 revenue of $1.11 billion, up 13%, and EPS of $3.40, up 21%, beating expectations and raising full-year guidance. Shares have surged about 50–55% year-to-date, trading near all-time highs. The company holds nearly half the global veterinary diagnostics market and generates about 79% of sales from recurring revenue. Institutional ownership stands at approximately 94%.
3 november 2025
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 november 2025
·
Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Technologies shares surged 1,300% from June lows, averting Nasdaq delisting and prompting the company to cancel a planned reverse split. Despite the rally, Opendoor posted a $29 million Q2 loss and expects Q3 revenue to fall sharply. The company named Kaz Nejatian CEO in September, shifting focus to AI-powered real estate. Wall Street analysts remain skeptical, with price targets below current levels.
3 november 2025
·
MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB named Chirantan “CJ” Desai as its next CEO, replacing Dev Ittycheria, who will step down in November 2025 after 11 years. Shares jumped about 9% in pre-market trading, nearing all-time highs, as the company raised its Q3 FY2026 outlook and analysts boosted price targets. Ittycheria will stay on as an advisor during the transition. Final Q3 results are due December 1, 2025.
3 november 2025
··
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 november 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 november 2025
·
Palantir’s $500 Billion AI Surge: Record Earnings, Stock Whiplash & What’s Next for PLTR

Palantir’s $500 Billion AI Surge: Record Earnings, Stock Whiplash & What’s Next for PLTR

Palantir’s Q3 2025 revenue surged 63% year-over-year to $1.18 billion, with adjusted EPS of $0.21, beating estimates and raising full-year guidance to $4.4 billion. Shares hit a record near $220 before dropping 4% as investors took profits. U.S. commercial revenue more than doubled, now surpassing government sales. The stock remains volatile, with analysts split over its high valuation.
4 november 2025
··
Lenskart IPO Frenzy: Sky-High Valuation Meets Surging Demand – Will Investors See Big Gains?

Lenskart IPO Frenzy: 7x Oversubscribed Amid Grey Market Jitters – Is Groww’s IPO the Safer Bet?

Lenskart’s ₹7,278 crore IPO was subscribed about 7 times, led by non-institutional bids at 10.2×. Shares list November 10, with grey market premiums cooling to ~14% above the ₹402 issue price. The IPO values Lenskart near ₹70,000 crore, or ~235× FY25 earnings, sparking debate over rich pricing. Brokerages mostly recommend subscribing, but some experts warn of stretched valuations and possible correction.
4 november 2025
Bitcoin Miner to AI Cloud Sensation: Why Iris Energy (IREN) Stock Is Soaring in 2025

From Bitcoin Miner to AI Cloud Powerhouse: Iris Energy’s Meteoric Rise (IREN Stock Soars on $9.7B Microsoft Deal)

Iris Energy (IREN) closed at $67.75 on Nov. 3, 2025, after announcing a $9.7 billion, five-year AI cloud contract with Microsoft, sending shares up 11.5%. The company’s market cap now tops $16.5 billion, up from $1 billion at the start of 2025. IREN posted FY2025 revenue of $501 million and net income of $86.9 million, driven by its pivot to AI cloud services and continued Bitcoin mining.
4 november 2025
···
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark shares plunged 14.6% on Nov. 3 to a 52-week low near $102 after announcing a $40 billion cash-and-stock deal to acquire Kenvue at a 46% premium. The drop erased about 15% of KMB’s market value, with the stock now down 21% year-over-year. Investors cited concerns over Kenvue’s litigation risks and debt load. KMB trades at 17.3× earnings, with a 4.9% dividend yield.
4 november 2025
··
Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture (SCNX) shares surged 40% to $0.99 pre-market Nov. 4 after its hypertension drug Arbli™ was added to major insurance formularies, expanding coverage to over 100 million people. The company reported just $0.13 million in revenue and a $20 million net loss over the past year. SCNX trades near $0.71, down from a 52-week high of $8.81. Analysts remain cautious, citing high cash burn and uncertain Arbli sales.
4 november 2025
·
Stanley Black & Decker (SWK) Stock: Big Earnings Beat, 5% Dividend – Rebound Ahead in 2025?

Stanley Black & Decker (SWK) Stock: Big Earnings Beat, 5% Dividend – Rebound Ahead in 2025?

Stanley Black & Decker shares closed at $66.36 on Nov. 3, 2025, down 2% and roughly 32% below their 52-week high. Q3 adjusted EPS beat estimates at $1.43, but revenue was flat at $3.75–3.76 billion and GAAP EPS fell to $0.34 due to a $169 million impairment charge. Management cut full-year profit guidance, citing higher costs. The dividend yield stands near 5%.
4 november 2025
··
Upwork Stock Soars on AI-Fueled Earnings Beat – Key Facts & Expert Outlook

Upwork Stock Soars on AI-Fueled Earnings Beat – Key Facts & Expert Outlook

Upwork reported Q3 2025 revenue of $201.7 million, beating estimates, and raised its full-year outlook above consensus. Shares surged nearly 20% to around $17 after the results. Wall Street analysts boosted price targets, with Goldman Sachs setting a $25 target citing AI-driven growth. AI-related freelance work on the platform jumped 53% year-over-year.
4 november 2025
···
Apple Stock Could Explode After New AI Chip Launch and iPhone 17 “Supercycle,” Analysts Say

Apple Stock Soars to Record High After Huge Q4 Earnings Beat – What’s Next for AAPL in 2025?

Apple traded near $269 on Nov. 4, 2025, close to its 52-week high of $277.32, with shares up 26% since August and market cap at $3.95 trillion. The company reported record Q4 revenue of $102.5 billion, up 8% year-over-year, and forecast double-digit iPhone sales growth for the holiday quarter. Analyst targets are split, with consensus near $285. Technical resistance is seen at $275–$280.
4 november 2025
···
1 … 272 273 274 275 276 … 279
Go toTop